IP Library Granted Patent US 7,622,564
Granted Patent B2
US 7,622,564 · App. 10/857,484 · Granted Nov 24, 2009

Prostate stem cell antigen (PSCA) variants and subsequences thereof

Assignee: Agensys, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,622,564
App. No.
10/857,484
Granted
Nov 24, 2009
Kind
B2
Abstract

PSCA and its encoded protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, propylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.

Claims (13)

1. An isolated polynucleotide, wherein the polynucleotide is selected from the group consisting of:

a nucleotide sequence that encodes a PSCA protein comprising the amino acid sequence of SEQ ID NO: 6547, 6548, 6549, 6550, 6551, 6552, 6553, or 6554.

2. The isolated polynucleotide of claim 1 , wherein the polynucleotide is selected from the group consisting of:

(a) a polynucleotide comprising the sequence of SEQ ID NO:6537, from nucleotide residue numbers 424 through 993, wherein the nucleotide residue at 521 is T;

(b) a polynucleotide comprising the sequence of SEQ ID NO:6537, from nucleotide residue numbers 424 through 993, wherein the nucleotide residue at 578 is C;

(c) a polynucleotide comprising the sequence of SEQ ID NO: 6537, from nucleotide residue numbers 424 through 993, wherein the nucleotide residue at 649 is G;

(d) a polynucleotide comprising the sequence of SEQ ID NO:6537, from nucleotide residue numbers 424 through 993, wherein the nucleotide residue at 653 is T;

(e) a polynucleotide comprising the sequence of SEQ ID NO: 6537, from nucleotide residue numbers 424 through 993, wherein the nucleotide residue at 721 is A;

(f) a polynucleotide comprising the sequence of SEQ ID NO: 6537, from nucleotide residue numbers 424 through 993, wherein the nucleotide residue at 781 is A;

(g) a polynucleotide comprising the sequence of SEQ ID NO:6537, from nucleotide residue numbers 424 through 993, wherein the nucleotide residue at 788 is G; and

(h) a polynucleotide comprising the sequence of SEQ ID NO:6537, from nucleotide residue numbers 424 through 993, wherein the nucleotide residue at 989 is A.

3. A recombinant expression vector comprising a polynucleotide of claim 2 .

4. An isolated host cell that contains an expression vector of claim 3 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2005
From: GE, WANGMAO; JAKOBOVITS, AYA; RAITANO, ARTHUR B.; CHALLITA-EID, PIA M.
To: AGENSYS, INC.
Reel/Frame 016491/0524 →
Continuity (2)
Provisional Application 6047506400 · May 30, 2003
Related Publication 20060029940A1 · Feb 9, 2006